Alexion Pharmaceuticals, Inc. (ALXN)
(Delayed Data from NSDQ)
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
3 ETFs to Watch Out for on Biotech Earnings
by Zacks Equity Research
Major players in the biotech space reported their second quarter 2017 results.
Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.
Alexion (ALXN) Tops Q2 Earnings, Sales; Shares Up
by Madhu Goel
Alexion surpassed earnings and sales expectations in the second quarter of 2017.
Why Alexion Pharmaceuticals (ALXN) Might Surprise This Earnings Season
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Intercept (ICPT) Beat Estimates this Earnings Season?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc.'s (ICPT) lead drug Ocaliva's uptake has been encouraging and we expect the company to throw light on its label expansion when it reports second-quarter results.
What's in the Cards for Exelixis (EXEL) in Q2 Earnings?
by Zacks Equity Research
Exelixis, Inc.'s (EXEL) efforts to develop its pipeline and uptake in Cabometyx sales should be the key areas of focus when the company reports second-quarter results.
Is Celgene (CELG) Poised For a Beat This Earnings Season?
by Zacks Equity Research
Celgene Corporation (CELG) is likely to beat on earnings estimates when it reports results on July 27 on the back of growth in Revlimid driven by share gains in important markets.
Are Options Traders Betting on a Big Move in Alexion Pharmaceuticals (ALXN) Stock?
by Zacks Equity Research
Investors in Alexion Pharmaceuticals, Inc. (ALXN) need to pay close attention to the stock based on moves in the options market lately.
Is a Beat in Store for Alexion (ALXN) this Earnings Season?
by Zacks Equity Research
Alexion Pharmaceuticals, Inc.'s (ALXN) drugs like Soliris and Strensiq have been performing well. Let's see if these lead the company to an earnings beat.
Is Gilead (GILD) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.
Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs
by Arpita Dutt
Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.
5 Top Multibagger Biotech Stocks to Buy in the 2nd Half
by Tirthankar Chakraborty
Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.
Alexion Reportedly Being Investigated by HHS, Shares Slip
by Zacks Equity Research
Shares of Alexion Pharmaceuticals, Inc. (ALXN) were down more than 3% on Thursday after a Bloomberg report stated that it is under investigation by the U.S. Department of Health and Human Services' (HHS) Office of Inspector General (OIG).
Top Stock Reports for Oracle, Allergan & Abbott
by Brian Hamilton
Today's Research Daily features new research reports on 12 major stocks, including Oracle (ORCL), Allergan (AGN), and Abbott (ABT).
Company News for June 15, 2017
by Zacks Equity Research
Companies in the News are: HRB,ALXN,UPS,NAME
Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug
by Arpita Dutt
Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.
Biogen Loses Top Executive Again, CFO Clancy to Join Alexion
by Zacks Equity Research
Biogen Inc.'s (BIIB) chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. (ALXN) next month.
Omeros (OMER) Lead Candidate Gets Breakthrough Designation
by Zacks Equity Research
Omeros Corporation (OMER) announced that the FDA granted breakthrough therapy designation to pipeline candidate OMS721.
Why Is Alexion (ALXN) Down 23% Since the Last Earnings Report?
by Zacks Equity Research
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Company News for May 24, 2017
by Zacks Equity Research
Companies in the News are: A,NOK,AAPL,ALXN,BG,GLEN
Biotech Stock Roundup: FDA Nod for Regeneron RA Drug, Amgen Hit by Study Data
by Arpita Dutt
Key highlights in the biotech sector include FDA approval for Regeneron's (REGN) Kevzara and data from Amgen and Celgene.
Here's Why Alexion Pharma (ALXN) Stock is Sinking Today
by Madeleine Johnson
On Tuesday, shares of Alexion Pharmaceuticals Inc. (ALXN) are sinking, down over about 8.5% in mid-morning trading after the company announced a series of changes to its executive team.
Alexion's (ALXN) Strensiq Results Positive in Long-Term Study
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) announced that researchers presented encouraging data on Strensiq at the European Calcified Tissue Society (ECTS) Congress in Austria.
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal
by Arpita Dutt
Quite a few deals were announced this week including by companies like Biogen (BIIB).
Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death
by Arpita Dutt
Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.